Anteris Technologies Global Corp. (AVR): Results for announcement to the market Name of entity
Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Results for announcement to the market Name of entity: Anteris Technologies Global Corp. (“ATGC”) ARBN: 677 960 235 Reporting period: For the quarter ended September 30, 2026 The attached Form 10-Q Quarterly Report for the quarter ended September 30, 2026 (the “Form
How this was made
The 30-second read
Why it matters
The filing is a routine earnings update for a small‑cap biotech; without specific financial metrics, market impact is expected to be modest.
Market read
Primary relevance is to investors in AVR; broader market effect is minimal.
What to watch
Related‑party payments of $576 k may hint at higher operating costs; the lack of disclosed revenue or profit figures leaves uncertainty.
Anteris files Q3 2026 supplementary disclosure with related-party payments of US$576 thousand; no results table in this exhibit
This Exhibit 99.1 contains no revenue, margin, earnings, cash flow or guidance figures. The only quantified item is the related-party payments disclosure, so no operating verdict can be supported from this document. The verdict is set to mixed as a neutral placeholder, not as a view on performance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Aggregate payments to related parties and their associates, Q3 2026other | $576K | – | – |
What to watch
- The Form 10-Q for the quarter ended September 30, 2026, which the release says has been filed with the SEC, for the full set of U.S. GAAP financial statements.
- The ASX announcement 'Anteris Announces Results for the Third Quarter of 2026', which the release says was lodged with the ASX on November 11, 2026.
- Any forward-looking guidance in the results announcement, which is not contained in this exhibit.
Balance sheet and cash flow
- Payments to related parties and their associates of US$576 thousand in Q3 2026 were included in cash flows from operating activities.
- No payments to related parties or their associates were included in cash flows from investing activities.
Analysis
This filing is a supplementary disclosure furnished under Item 2.02 alongside a Form 10-Q for the quarter ended September 30, 2026. It states that the 10-Q contains the condensed consolidated financial statements prepared under U.S. GAAP and denominated in U.S. dollars, but the statements themselves are not reproduced in this exhibit. As a result, the document contains no revenue, gross margin, operating expense, operating income, net income, EPS, cash, debt or guidance figures.
The one quantified item is the aggregate amount of payments to related parties and their associates in the third quarter of 2026, which the company puts at US$576 thousand. The company states that the amount includes fees paid to non-executive directors and salary payments to the CEO, President and CFO. It also states that these payments were included in operating cash flows, and that there were no related-party payments in investing cash flows. No prior-period comparison for this item is printed, so no change can be shown.
The release refers readers to two other documents for business activity and results: the Form 10-Q and an ASX announcement dated November 11, 2026. Neither is included in the text provided, so no assessment of demand, product volumes, margins, cash position or outlook can be made from this filing. The date of the ASX announcement is also later than this filing's timestamp of November 10, 2026, which the reader should keep in mind when matching the two documents.
For this read, the relevant figures are the 10-Q and the ASX results announcement. Until those are reviewed, the only verifiable statement about the period is the related-party payment figure and its classification within operating cash flows.
Not in the filing
stated, not guessed- Total revenue and all revenue sub-lines for Q3 2026, and prior-year and prior-quarter comparatives.
- Cost of sales, gross margin, operating expenses (R&D, SG&A, other), and operating income for Q3 2026.
- Net income or loss, GAAP and non-GAAP EPS, interest and tax for Q3 2026.
- Segment or geographic revenue breakdown.
- Operating, investing and free cash flow totals, cash balance, debt, total assets and equity.
- Capital returns such as share repurchases or dividends, if any.
- Operating KPIs, such as procedure or unit volumes, if disclosed.
- Any forward-looking guidance for revenue, gross margin, operating expenses or tax rate.
- Prior-year and prior-quarter comparatives for the related-party payments figure.
- The full text of the Form 10-Q, which the release says was filed but is not included.
- The full text of the ASX announcement 'Anteris Announces Results for the Third Quarter of 2026', which the release says was lodged on November 11, 2026.
- Management quotes, since the exhibit contains no executive commentary.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Anteris Technologies Global Corp. (NASDAQ: AVR) filed a Form 8‑K announcing its Q3 2026 results and related‑party payments, the first public disclosure of this quarter.
Ticker impact
SEC Form 8‑K reports Anteris Technologies' Q3 2026 results and related‑party payments of $576 k, the first public disclosure of this quarter.
likely limited movement as investors await detailed financials; modest pressure if results miss expectations
The filing is a routine earnings report for a small‑cap biotech; without earnings numbers or guidance, market reaction is expected to be muted.
Market effects
Provides a data point for the structural‑heart‑device sector but unlikely to shift sector sentiment.
Minor impact on US and Australian biotech markets; no broader regional effect.
Limited to investors tracking small‑cap medical‑device stocks.
Counterpoint
If the company’s detailed financials later reveal a revenue shortfall, the stock could face a sharper decline than anticipated.
Key entities
- companyAnteris Technologies Global Corp.
Global healthcare company developing structural‑heart devices, listed on NASDAQ under AVR.




